Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2.

Derniame S, Perazzo J, Lee F, Domogala A, Escobedo-Cousin M, Alnabhan R, Luevano M, Pedroza-Pacheco I, Cooper N, Madrigal A, Saudemont A.

Cytotherapy. 2014 Oct;16(10):1409-18. doi: 10.1016/j.jcyt.2014.05.010. Epub 2014 Jun 23.

PMID:
24969967
2.

Unique effects of mycophenolate mofetil on cord blood T cells: implications for GVHD prophylaxis.

Derniame S, Lee F, Domogala A, Madrigal A, Saudemont A.

Transplantation. 2014 Apr 27;97(8):870-8. doi: 10.1097/01.TP.0000438203.19595.3f.

PMID:
24670298
3.

Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.

Lin SJ, Kuo ML.

Cytotherapy. 2008;10(4):397-405. doi: 10.1080/14653240802129885.

PMID:
18574772
4.

Differential cyclosporin-A sensitivity on survival and activation of umbilical cord and adult peripheral blood CD4+ T cells.

Lin SJ, Kuo ML, Cheng PJ, Hsiao SS.

Transpl Immunol. 2007 Nov;18(2):172-8. Epub 2007 Jun 19.

PMID:
18005864
6.

Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen.

Ohata K, Espinoza JL, Lu X, Kondo Y, Nakao S.

Biol Blood Marrow Transplant. 2011 Feb;17(2):205-13. doi: 10.1016/j.bbmt.2010.08.014. Epub 2010 Aug 22.

7.

Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.

Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M.

Am J Hematol. 2015 Feb;90(2):144-8. doi: 10.1002/ajh.23882. Epub 2014 Nov 19.

8.

Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.

Vacher-Coponat H, Brunet C, Moal V, Loundou A, Bonnet E, Lyonnet L, Ravet S, Sampol-Manos E, Sampol J, Berland Y, George FD, Paul P.

Transplantation. 2006 Aug 27;82(4):558-66.

PMID:
16926601
9.

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

Bornhäuser M, Schuler U, Pörksen G, Naumann R, Geissler G, Thiede C, Schwerdtfeger R, Ehninger G, Thiede HM.

Transplantation. 1999 Feb 27;67(4):499-504.

PMID:
10071016
10.

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.

Bremm M, Huenecke S, Zimmermann O, Pfirrmann V, Quaiser A, Bonig H, Soerensen J, Klingebiel T, Rettinger E, Bader P, Cappel C.

J Transl Med. 2016 Sep 13;14:264. doi: 10.1186/s12967-016-1024-4.

11.

[Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].

Wang J, Song X, Zhang W, Tong S, Hou J, Chen L, Lou J, Li H, Ding X, Min B.

Zhonghua Yi Xue Za Zhi. 2002 Apr 25;82(8):507-10. Chinese.

PMID:
12133492
12.

Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil.

Miroux C, Morales O, Ouaguia L, Aoudjehane L, Boleslawski E, Pancré V, de Launoit Y, Calmus Y, Conti F, Delhem N.

Transplant Proc. 2012 Nov;44(9):2834-9. doi: 10.1016/j.transproceed.2012.09.091.

PMID:
23146536
13.

Functional analyses of cord blood natural killer cells and T cells: a distinctive interleukin-18 response.

Nomura A, Takada H, Jin CH, Tanaka T, Ohga S, Hara T.

Exp Hematol. 2001 Oct;29(10):1169-76. Review.

PMID:
11602318
14.

Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.

Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1031-8. doi: 10.1016/j.bbmt.2008.06.016.

15.

[Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].

Huang H, Zheng W, Lin M, Fu J, Zhang R.

Zhonghua Xue Ye Xue Za Zhi. 2002 Apr;23(4):191-3. Chinese.

PMID:
12133455
16.

Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture.

Tomchuck SL, Leung WH, Dallas MH.

Biol Blood Marrow Transplant. 2015 Jan;21(1):39-49. doi: 10.1016/j.bbmt.2014.10.014. Epub 2014 Oct 18.

17.

Differential activation of cord blood and peripheral blood natural killer cells by cytokines.

Alnabhan R, Madrigal A, Saudemont A.

Cytotherapy. 2015 Jan;17(1):73-85. doi: 10.1016/j.jcyt.2014.08.003. Epub 2014 Sep 22.

PMID:
25248279
18.

The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation.

Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, Saudemont A.

Hum Immunol. 2012 Mar;73(3):248-57. doi: 10.1016/j.humimm.2011.12.015. Epub 2011 Dec 28.

PMID:
22234167
19.

Cytotoxicity of human cord blood natural killer cells is enhanced by recombinant interleukin-15.

Saghafi S, Pourfathollah AA, Kheirandish M, Azimdoust A, Behnia M, Shahjahani M, Moin M.

Iran J Allergy Asthma Immunol. 2010 Jun;9(2):69-77. doi: 09.02/ijaai.6977.

20.

Natural Killer Cell Activating Receptor NKG2D Is Involved in the Immunosuppressive Effects of Mycophenolate Mofetil and Hepatitis B Virus Infection.

Dong S, Geng L, Shen MD, Zheng SS.

Am J Med Sci. 2015 May;349(5):432-7. doi: 10.1097/MAJ.0000000000000442.

PMID:
25828197

Supplemental Content

Support Center